Ipsen

Ipsen is one of the few European specialty-pharma names where the founding family still controls the strategy — Mayroux family holdings via Mayroux SAS hold 56% of the equity and 73% of voting rights. That structural control is why Ipsen has been able to make three contrarian acquisitions in five years (Albireo for Bylvay, Epizyme for Tazverik, and the late-2025 Vincerx oncology pipeline buy) without activist pushback.

The 2026 commercial reality is split between three franchises. Bylvay (odevixibat, in pediatric cholestatic liver diseases) is the surprise winner — first approved 2021, FY2025 sales hit EUR 285 M, up 71% YoY, with EU EMA expansion to PFIC subtypes 1+2 in 2025 and Alagille label-expansion approval pending Q3/2026. Cabometyx (cabozantinib, licensed from Exelixis for ex-US ex-Japan) is still the cash cow at EUR 798 M FY2025 — but the European patent cliff hits late 2027. Onivyde (irinotecan liposomal) just got the NAPOLI-3 first-line pancreatic cancer label expansion in Q1/2026 — peak sales projections jumped from EUR 350 M to EUR 800 M.

The strategic question for 2026: can Ipsen successfully transition from a Cabometyx-dependent specialty pharma to a Bylvay + Onivyde + new-launches franchise before the patent cliff bites?

Top holders Q1/2026: Mayroux SAS / Mayroux family 56% (controlling), Capital Group 4.8%, Norges Bank 3.6%, Pictet Asset Management 2.1%. No US celebrity-investor positions — Ipsen is a deeply specialist European-pharma name.

Most interesting institutional move: Polar Capital Healthcare team disclosed a new 1.8% position in March 2026, citing the NAPOLI-3 Onivyde upside as underpriced. Generation Investment Management (Al Gore-affiliated) added 22% to existing position in Q1/2026.

Insider activity: CEO David Loew bought EUR 1.1 M of stock in November 2025 at EUR 138 (now EUR 166, +20%). CFO Aymeric Le Chatelier exercised options and held 100% of resulting shares in Feb 2026 — first time in 4 years he has not partial-sold on exercise. Mayroux family has not added or trimmed since 2019.

Short interest is at 1.4%, near the 5-year low — consistent with institutional comfort that Cabometyx-cliff is well telegraphed and adequately replaced.

Forward P/E of 12.3x is unusually cheap for a specialty pharma with a 9% revenue-growth profile and three growth assets entering label expansion. European specialty-pharma peer median is 16.5x (Indivior 13x, Recordati 18x, UCB 22x). The 30% discount to peers is driven entirely by the Cabometyx-cliff narrative. EV/EBITDA at 9.1x is below 5-year average of 11.4x. Consensus PT EUR 195 (range EUR 155-225); Berenberg most bullish at EUR 230 (assumes Onivyde EUR 800 M peak), JP Morgan most bearish at EUR 145 (Cabometyx-cliff worse than feared). Implied probability of successful franchise transition in current price is ~50%.

1. Q3 2026: Bylvay Alagille label expansion EMA decision — direct revenue tailwind
2. Q4 2026: Bylvay biliary atresia Phase 3 readout — major pipeline catalyst
3. FY 2027 H1: Cabometyx EU patent cliff begins — visibility on biosimilar erosion pace

Ipsen is a transition trade for investors who believe specialty pharma can be priced through a patent cliff if the replacement pipeline is real. The Mayroux family structural control is a feature, not a bug — it disciplines capital allocation and prevents activist short-termism. I find the asymmetry compelling: 12.3x forward with three label-expansion catalysts in the next 18 months, against a peer median of 16.5x. The biggest risk is that biosimilar Cabometyx hits faster than modeled, but even that is a known unknown. I would size IPN as a 2-3% pharma allocation, with add triggers on either Bylvay biliary-atresia positive readout or Onivyde NAPOLI-3 first European reimbursement win. Daniel-style: I prefer this to most US biotech because the cash flow already pays for the pipeline.